An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): A possible prognostic biomarker

World Journal of Surgical Oncology

Volumn 14, Issue 1, 2016, Pages

  Wei, Kanglai ^a   Ye, Zhihua ^a   Li, Zuyun ^a   Dang, Yiwu ^a   Chen, Xin ^a   Huang, Na ^a   Bao, Chongxi ^a   Gan, Tingqing ^a   Yang, Lihua ^a   Chen, Gang ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Cyclin dependent kinase 5; Immunohistochemistry; Lung neoplasms; Neoplasm metastasis; Tissue array analysis

Indexed keywords

CYCLIN DEPENDENT KINASE 5; CDK5 PROTEIN, HUMAN; TUMOR MARKER;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CDK5 GENE; COLLOID CARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG PARENCHYMA; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; NON SMALL CELL LUNG CANCER; ONCOGENE; SMALL CELL LUNG CANCER; VERY ELDERLY; ADENOCARCINOMA; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; LUNG; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR INVASION;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE 5; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 84960121938     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/s12957-016-0787-7     Document Type: Article

References (29)

1. Barrow TM, Michels KB. Epigenetic epidemiology of cancer. Biochem Biophys Res Commun. 2014;455(1-2):70-83. doi: 10.1016/j.bbrc.2014.08.002.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29. doi: 10.3322/caac.21254.
3. Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X, et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014;26(1):48-58. doi: 10.3978/j.issn.1000-9604.2014.01.08.
4. Brothers JF, Hijazi K, Mascaux C, El-Zein RA, Spitz MR, Spira A. Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-national lung screening trial era. BMC Med. 2013;11:168. doi: 10.1186/1741-7015-11-168.
5. Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13:158. doi: 10.1186/1471-2407-13-158.
6. Zhang C, Huang C, Wang J, Wang X, Li K. Maintenance or consolidation therapy for non-small-cell lung cancer: a meta-analysis involving 5841 subjects. Clin Lung Cancer. 2015. doi:10.1016/j.cllc.2015.01.002
7. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252-71. doi: 10.3322/caac.21235.
8. Barr Kumarakulasinghe N, Zanwijk NV, Soo RA. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Respirology. 2015. doi:10.1111/resp.12490
9. Parums DV. Current status of targeted therapy in non-small cell lung cancer. Drugs Today. 2014;50(7):503-25. doi: 10.1358/dot.2014.50.7.2185913.
10. Gerard C, Tyson JJ, Coudreuse D, Novak B. Cell cycle control by a minimal cdk network. PLoS Comput Biol. 2015;11(2):e1004056. doi: 10.1371/journal.pcbi.1004056.
11. Liang Q, Li L, Zhang J, Lei Y, Wang L, Liu DX, et al. CDK5 is essential for TGF-beta1-induced epithelial-mesenchymal transition and breast cancer progression. Scientific Reports. 2013;3:2932. doi: 10.1038/srep02932.
12. Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D et al. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma-a novel therapeutic approach. J Hepatol. 2015. doi:10.1016/j.jhep.2015.01.031
13. Xie W, Wang H, He Y, Li D, Gong L, Zhang Y. CDK5 and its activator P35 in normal pituitary and in pituitary adenomas: relationship to VEGF expression. Int J Biol Sci. 2014;10(2):192-9. doi: 10.7150/ijbs.7770.
14. Lindqvist J, Imanishi SY, Torvaldson E, Malinen M, Remes M, Orn F et al. Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells. Molecular biology of the cell. 2015. doi:10.1091/mbc.E14-12-1634
15. Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, Siegl V, et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell. 2013;24(4):499-511. doi: 10.1016/j.ccr.2013.08.027.
16. Lockwood WW, Chari R, Coe BP, Girard L, Macaulay C, Lam S, et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene. 2008;27(33):4615-24. doi: 10.1038/onc.2008.98.
17. Cao L, Zhou J, Zhang J, Wu S, Yang X, Zhao X et al. Cyclin dependent kinase 5 decreases in gastric cancer and its nuclear accumulation suppresses gastric tumorigenesis. Clin Cancer Res. 2015. doi:10.1158/1078-0432.CCR-14-1950
18. Levacque Z, Rosales JL, Lee KY. Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients. Cell Cycle. 2012;11(21):4093-5. doi: 10.4161/cc.21886.
19. Bidkhori G, Narimani Z, Hosseini Ashtiani S, Moeini A, Nowzari-Dalini A, Masoudi-Nejad A. Reconstruction of an integrated genome-scale co-expression network reveals key modules involved in lung adenocarcinoma. PLoS One. 2013;8(7):e67552. doi: 10.1371/journal.pone.0067552.
20. Choi HS, Lee Y, Park KH, Sung JS, Lee JE, Shin ES, et al. Single-nucleotide polymorphisms in the promoter of the CDK5 gene and lung cancer risk in a Korean population. J Hum Genet. 2009;54(5):298-303. doi: 10.1038/jhg.2009.29.
21. Demelash A, Rudrabhatla P, Pant HC, Wang X, Amin ND, McWhite CD, et al. Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway. Mol Biol Cell. 2012;23(15):2856-66. doi: 10.1091/mbc.E10-12-1010.
22. Tripathi BK, Qian X, Mertins P, Wang D, Papageorge AG, Carr SA, et al. CDK5 is a major regulator of the tumor suppressor DLC1. J Cell Biol. 2014;207(5):627-42. doi: 10.1083/jcb.201405105.
23. Liu JL, Wang XY, Huang BX, Zhu F, Zhang RG, Wu G. Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis. Med Oncol. 2011;28(3):673-8. doi: 10.1007/s12032-010-9510-7.
24. Shah K, Lahiri DK. Cdk5 activity in the brain-multiple paths of regulation. J Cell Sci. 2014;127(Pt 11):2391-400. doi: 10.1242/jcs.147553.
25. Nishimura YV, Shikanai M, Hoshino M, Ohshima T, Nabeshima Y, Mizutani K, et al. Cdk5 and its substrates, Dcx and p27kip1, regulate cytoplasmic dilation formation and nuclear elongation in migrating neurons. Development. 2014;141(18):3540-50. doi: 10.1242/dev.111294.
26. Xu S, Li X, Gong Z, Wang W, Li Y, Nair BC, et al. Proteomic analysis of the human cyclin-dependent kinase family reveals a novel CDK5 complex involved in cell growth and migration. Mol Cell Proteomics. 2014;13(11):2986-3000. doi: 10.1074/mcp.M113.036699.
27. Kimura T, Ishiguro K, Hisanaga S. Physiological and pathological phosphorylation of tau by Cdk5. Front Mol Neurosci. 2014;7:65. doi: 10.3389/fnmol.2014.00065.
28. Shan YS, Chen YL, Lai MD, Hsu HP. Nestin predicts a favorable prognosis in early ampullary adenocarcinoma and functions as a promoter of metastasis in advanced cancer. Oncol Rep. 2015;33(1):40-8. doi: 10.3892/or.2014.3588.
29. Miki M, Ball DW, Linnoila RI. Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung. Lung Cancer. 2012;75(1):58-65. doi: 10.1016/j.lungcan.2011.05.019.